Patients who had FLT3-ITD negative AML with co-occurring high-risk mutations (TET2, ASXL1 and/or PHF6) had survival similar to patients with intermediate IGP risk AML and therefore did not merit reclassification into an unfavorable risk group. Here, FLT3 is linked to acute myeloid leukemia.